A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting.
Cancer Chemother Pharmacol
; 81(2): 339-345, 2018 02.
Article
in En
| MEDLINE
| ID: mdl-29234921
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Agents, Alkylating
/
Small Cell Lung Carcinoma
/
Ifosfamide
/
Lung Neoplasms
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Cancer Chemother Pharmacol
Year:
2018
Document type:
Article
Affiliation country:
Japan
Country of publication:
Germany